Trial Search Results

Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer

Trial of sorafenib versus placebo in the treatment of locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine

Stanford is currently not accepting patients for this trial.

Lead Sponsor:


Collaborator: Amgen


  • Drug: Sorafenib (Nexavar, BAY43-9006)
  • Drug: Placebo


Phase 3


Inclusion Criteria:

   - Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular
   and Hurthle cell)

   - Poorly differentiated and other thyroid variants (e.g. insular, tall cell, etc.) are
   eligible provided that the histology has no medullary differentiation nor anaplastic

   - Progression within 14 months (RECIST [Response Evaluation Criteria in Solid Tumors]
   should be used as a basis for the assessment of disease progression)

   - RAI (radioactive iodine) refractory

Exclusion Criteria:

   - Histologic subtypes of thyroid cancer other than differentiated (i.e. like anaplastic
   and medullary carcinoma, lymphoma or sarcoma)

   - Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies
   (licensed or investigational) that target VEGF (vascular endothelial growth factor) or
   VEGF Receptors or other targeted agents

   - Prior anti-cancer treatment for thyroid cancer with use of chemotherapy (low dose
   chemotherapy for radiosensitization is allowed) or Thalidomide or any of its

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting